When was Cellino founded?

Cellino was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Cellino located?

Cellino is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of Cellino?

Nabiha Saklayen of Cellino. They have also founded 1 company.

How many employees does Cellino have?

As of Apr 30, 2026, the latest employee count at Cellino is 109.

Is Cellino a funded company?

Cellino is a funded company, having raised a total of $125M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Nov 02, 2017.

When was the latest funding round of Cellino?

Cellino's latest funding was a $***** Series A round on Sep 18, 2024, with participation from 0 investor. Its primary sector is Cell Therapy. In United States, the Cell Therapy sector has seen $379M in funding in 2026 to date.

Where does Cellino rank among its competitors?

Cellino ranks 12th amongst 667 active competitors, of which 228 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Adocia, which secured $11.7M in Dec, 2025.

Who are the top competitors of Cellino?

Cellino's top competitors include Sana Biotechnology, argenx and Tenaya Therapeutics. Among them, Adocia secured the most recent funding round in December, 2025.

Cellino - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of autologous cell therapies. The company has developed an AI-guided laser editing platform, single-cell laser processing, and robotics to generate autologous induced pluripotent stem cells for regenerative medicines for diseases like Parkinson’s, diabetes, and heart disease.

Website: cellinobio.com
Social
Email ID: *****@cellinobio.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Series A

Total Funding

$125M in 6 rounds

Latest Funding Round

Series A, Sep 18, 2024, $*****

Investors

Khosla Ventures & 8 more

Ranked

12^th among 667 active competitors

Employee Count

109 as on Apr 30, 2026

Similar Companies

Sana Biotechnology & 721 more

View Cellino's full profile

Cellino is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cellino Biotech, Inc. CIN: 822481403 , United States, Active	Dec 26, 999	-	63 (As on Dec 31, 2024)	-

Cellino has raised a total funding of $125M over 6 rounds. Its first funding round was on Nov 02, 2017. Cellino has 9 institutional investors.

Here is the list of recent funding rounds of Cellino:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 18, 2024	3742164	Series A	9281506	9221431	2778371	8864139
Jan 25, 2022	6350148	Series A	6935964	4302655	2265596	Felicis Ventures & 2 more
Feb 01, 2021	2896870	Seed	4001324	9205849	Khosla Ventures & 1 more	Humboldt Fund & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Cellino's funding rounds and investors

The founders of Cellino are Stan Wang, Matthias Wagner, Marinna Madrid and Nabiha Saklayen. Nabiha Saklayen is the CEO of Cellino.

Here are the details of Cellino's key team members:

Stan Wang: Co-Founder & CSO of Cellino and founder of 1 other company.
Contact Info: 1 email address
Matthias Wagner: Co-Founder & CTO of Cellino.
Contact Info: 1 email address
Marinna Madrid: Co-Founder of Cellino.
Contact Info: 1 email address
Nabiha Saklayen: Co-Founder & CEO of Cellino.
Contact Info: 1 email address

View details of Cellino's Founder profiles and Board Members

Cellino's employee count trend

Cellino has 109 employees as of Apr 26. Here is Cellino's employee count trend over the years:

Uncover Cellino's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellino include Sana Biotechnology, argenx and Tenaya Therapeutics. Here is the list of Top 10 competitors of Cellino, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
3rd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	Fidelity Investments, RA Capital Management ... & 7 others	70/100
4th	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	68/100
5th	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
6th	Kiniksa Pharmaceuticals 2015, Lexington (United States), Public	Developer of therapeutics for multiple diseases treatment	$320M	Fidelity Investments, Sofinnova Investments ... & 8 others	66/100
7th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
8th	Esperion Therapeutics 1998, Ann Arbor (United States), Acquired	Developer of lipoprotein cholesterol (LDL-C) lowering therapies	$107M	Alta Partners, Aisling Capital & 16 others	66/100
9th	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	Bain Capital Life Sciences, RTW Investments ... & 12 others	65/100
10th	Aspen Neuroscience 2018, San Diego (United States), Series C	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Orbimed, Revelation Partners & 22 others	65/100
12th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Khosla Ventures, Felicis Ventures & 7 others	65/100